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OBJECTIVES: Managed care and other decision makers need
sound comparative information to support the formulary selec-
tion process and reimbursement decisions for the treatment of
migraine. The objective of this study was to compare currently
marketed triptan therapies using number-needed-to-treat (NNT)
and doses-needed-to-treat (DNT) measures. DNT was further
used to derive triptan treatment cost to achieve 100 successfully
treated patients. METHODS: Using published meta-analysis
data to categorize patients as treatment success or failure, an
NNT and a DNT were derived for each triptan. Treatment
success was deﬁned as achieving a two-hour pain response, sus-
tained through 24 hours postdose. Costs were derived by multi-
plying DNT by the average wholesale price subtracted by 15%
for each triptan. RESULTS: Eletriptan 40mg had the lowest
NNT, with 361 patients needing to be treated in order to have
100 patients achieve clinical beneﬁt. Rizatriptan 5mg had the
highest NNT (597 patients). Eletriptan 40mg required 389 
doses to successfully treat 100 patients—the lowest number of
doses of the triptans considered; rizatriptan 5mg required the
highest number (662 doses). Eletriptan 40mg had the lowest
total triptan cost of $5639 to successfully treat 100 patients. 
The highest total triptan cost of treatment was for naratriptan
2.5mg, at a cost of $11,144. CONCLUSIONS: Eletriptan 
40mg provides the best value in terms of the lowest DNT.
Eletriptan 40mg also was found to have the lowest total 
triptan cost to successfully treat 100 patients. Future research
should further explore the utility of DNT in managed care 
decision-making.
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OBJECTIVES: The objective of this study was to compare the
cost-effectiveness of eletriptan to zolmitriptan using 24-hour 
sustained headache pain response as the measure of migraine
treatment outcome. METHODS: This economic analysis was
based on data derived from a randomized, multi-center, double-
blind, double-dummy, parallel group, placebo controlled, single-
attack study of treatment for acute migraine. Patients enrolled
in the clinical trial were randomized to eletriptan 40mg,
zolmitriptan 2.5mg, or placebo. The clinical efﬁcacy data from
the two active treatment arms were combined with published
drug cost data to assess the relative cost-effectiveness of eletrip-
tan versus zolmitriptan. The cost per successfully treated patient
(CPSTP) was calculated for both treatment groups as the ratio
of the total triptan cost for treating all patients to the number of
patients classiﬁed as being successfully treated. The health
authority costs included eletriptan 40mg at 3.40€ per dose and
zolmitriptan 2.5mg at 3.58€ per dose. The 24-hour sustained
headache pain response rate was the effectiveness measure used
in the denominator of the CPSTP ratio. RESULTS: For the 24-
hour sustained headache pain response measure, a signiﬁcantly
larger proportion of patients were successfully treated with
eletriptan versus zolmitriptan (p = 0.0099). The CPSTP estimates
were 10.34€ (95% CI: 8.97€–12.17€) for eletriptan and 14.65€
(95% CI: 12.53€–17.45€) for zolmitriptan. CONCLUSIONS:
For the 24-hour sustained headache response endpoint, eletrip-
tan 40mg performed signiﬁcantly better than zolmitriptan 
2.5mg. For the cost per successfully treated patient, eletriptan
costs were signiﬁcantly lower compared to zolmitriptan costs.
The results of this study add to the body of clinical and economic
evidence supporting the use of eletriptan for the treatment of
acute migraine, and can be used to assist decision makers in the
allocation of scarce resources.
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OBJECTIVES: To relate migraine frequency to general health
status among a cohort of migraineurs. METHODS: We con-
ducted a cross-sectional survey of patients aged ≥ 18 years 
diagnosed with episodic migraine (and no migraine at time of
recruitment) and ≥ one-year of migraine history. Patients were
enrolled at three geographically diverse US centers representing
varied models of care. Subjects completed a questionnaire that
included demographic/clinical information and the Health Utili-
ties Index Mark three (HUI3). Multivariate analyses were under-
taken to assess the relationship between HUI3 and migraine
frequency, controlling for study center, demographics (age, sex,
income) and clinical characteristics (comorbidities, migraine
severity, presence of aura, duration, disruptiveness of migraine
to family and friends). RESULTS: The mean age of subjects (n
= 150) was 44 years and 87% were female. Patients averaged 24
years of migraine history, and 41% reported using preventive
medication. Mean (±SD) monthly migraine frequency was 4.4
(±3.6), with 34% reporting £ two migraines per month and 20%
reporting > six per month. Mean (±SD) HUI3 score was 0.62
(±0.26) and the median was 0.66. Migraine frequency was sig-
niﬁcantly (p < 0.05) and negatively associated with HUI3 scores.
Adjusted mean HUI3 score was 0.64 for those with £ two
migraines per month, 0.57 for those with > two to four migraines
per month, 0.53 for those with > four to six migraines per
month, and 0.50 for those with > six migraines per month.
Migraine frequency was positively associated with higher levels
of impairment on the emotion, cognition, and pain components
of the HUI3. CONCLUSIONS: Migraineurs suffer substantial
impairment in health utility, with more frequent migraines asso-
ciated with greater impairment. These utility data are useful for
assessing the burden of migraine headache, and for evaluating
the impact and cost-effectiveness of interventions that reduce the
rate of migraine attacks.
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OBJECTIVE: Initial development of a new measure for assess-
ing patient satisfaction with treatment for migraine headaches
utilizes a four-part conceptual model incorporating patient
